KACTUS Unveils Ultra-low Endotoxin Recombinant Protein Line — Powering Cleaner, Faster, Smarter Drug Discovery

KACTUS is thrilled to announce the official launch of our ultra-low endotoxin recombinant protein catalog products, purpose-built to supercharge your research with the highest purity and performance standards in the industry. Whether you're pushing the frontiers of immunotherapy, refining vaccine platforms, or optimizing preclinical models, our ultra-low endotoxin product portfolio is designed to deliver results you can trust, right out of the box.

Endotoxin has long been a silent disruptor in animal immunization and sensitive biological assays. Our ultra-low endotoxin protein collection is meticulously engineered to eliminate this variable, empowering researchers to generate cleaner data, reduce variability, and accelerate the path from bench to clinic.

What to expect from our ultra-low endotoxin recombinant proteins:

• Endotoxin levels <0.01 EU/µg or even <0.001 EU/µg tested by the LAL method

• Consistent biological activity, batch-to-batch

• Applicable for animal immunization, cell-based assays, or any bioassays that require low endotoxin

• Available in human and cynomolgus species and various tag formats for broad compatibility

At KACTUS, we’re passionate about removing roadblocks to innovation. With this launch, we are giving scientists the high-purity tools they need to run faster experiments, make stronger conclusions, and move discoveries forward with confidence.”

The ultra-low endotoxin recombinant proteins are now available for immediate order. Browse our full ultra-low endotoxin products at https://kactusbio.com/pages/ultra-low-endotoxin-recombinant-proteins or contact us at support@kactusbio.us to learn more!

Related Readings: Why Endotoxin Testing Matters: Safeguarding Recombinant Protein Applications in Immunology and Drug Discovery